Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study

Sequential Laser Iridotomy uses argon and Nd:yag laser in the first and second steps, respectively. Using q-switched 532 nm laser in the second step is hypothesized to be as good and effective as the conventional Nd:yag laser, because it selectively targets pigmented cells and delivers a short pulse duration of 3 nanoseconds, causing less thermal and collateral damage.

Study Overview

Detailed Description

Laser iridotomy is an established procedure in the management of angle closure glaucoma (ACG) and for prophylaxis in the fellow eyes.

Sequential argon-YAG (SAY) laser iridotomy is the serial use of argon and Nd:YAG laser at the same treatment session to create an iridotomy. Argon laser is initially used to make a bore of about 500 μm in diameter to an estimated two-thirds iris thickness in depth. The 1064 nm Q-switched neodymium YAG laser is next used to complete the perforation1. Others aim the argon laser at the iris surface to create a crater, and the next shots at the base of the crater until the iris is penetrated as evidenced by a pigment plume. The Nd:YAG laser then creates a photodisruptive explosion to enlarge the opening.

This procedure was first described by Zborwski-Gutman in 1988. Sixteen eyes were treated with two argon stretch burns and up to 35 penetrating burns that produced an iridotomy that was either imperforate or inadequate. Nd:YAG laser was used to complete the iridotomy. In all the eyes, the iridotomy was achieved in one session, and two eyes had a moderate increase in pressure that was easily controlled. The authors found that the total energy levels for each laser modality were significantly lower than those previously reported using either laser alone. The authors concluded that the sequential technique is safe and effective, and is recommended for iridotomy in difficult iris types.

Lim et al in 1996 did a prospective study that compared argon laser iridotomy and SAY in dark irides. Twenty-four eyes of 17 patients were involved; and 13 underwent argon laser iridotomies, and 11 underwent SAY. The argon laser settings were standardized at 1.2 W, 50 μm spot size and 0.1 second duration. The Nd: YAG laser was set at 2.5 mJ and single-pulse shots were used. All the iridotomies were completed in a single session. The mean total energy used for argon laser iridotomy was 8.28 J; while for SAY, 3.12 J was used for the argon laser stage and 7.5 mJ for the Nd:YAG stage. The authors concluded that the total argon laser energy used can be reduced by 2.65 times using the SAY technique.

The SAY technique is ideal in Asian eyes because it avoids the disadvantages of argon and Nd-YAG laser, when they are used as separate methods.

In SAY, bleeding is uncommon and microscopic, unlike in Nd:YAG iridotomy wherein it can be severe enough to cause the abortion of the procedure. Nd:YAG iridotomy is rarely associated with focal lens or retina damage; but argon laser can cause inadvertent focal lens damage.

By using ND:YAG laser as second stage laser, SAY iridotomy avoids the tedious and hazardous chipping enlargement phase of argon iridotomy that can contribute to retinal damage. Likewise, with the argon laser pre-treatment, excessive pigment and debris dispersion, iris splintering, and high energy levels needed for iris perforation from a Nd:YAG iridotomy in an Asian eye is avoided. In Ho's series of 20 patients who underwent SAY, only one eye had iridotomy closure during a mean follow-up period of 14 months.

Q-switched 532 nm frequency-doubled neodymium:yytrium-aluminum-garnet (fd-Nd:YAG) laser has been used in the recent years for selective laser trabeculoplasty (SLT). It was developed by Latina et.al. to selectively target pigmented trabecular meshwork (TM) cells without causing thermal or collateral damage to the nonpigmented cells or structures of the TM. This is so because it is able to deliver a short pulse duration of 3 nanoseconds while selectively lysing intracellular melanosomes, killing pigmented cells and leaving cellular membranes and neighboring nonpigmented cells intact. This technique delivers less than 1% of the energy of ALT, with shorter pulse durations and consequently higher power levels. Latina noted bubble formation at higher fluence, but this is not from boiling tissue, but are microcellular cavitation effects.

Study Type

Interventional

Enrollment (Anticipated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Singapore, Singapore, 119074
        • National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • More than 21 years old
  • Able to give informed consent
  • Diagnosis of either: chronic angle closure glaucoma (CACG), primary angle closure (PAC), primary angle closure suspect (PACS) or fellow eyes of acute angle closure glaucoma (AACG), and in need of a laser iridotomy

Exclusion Criteria:

  • History of any prior laser treatment or intraocular surgery to the eye
  • History of any corneal disease
  • Any ocular infection/ inflammation within the last two months
  • Inability to give informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Intraocular pressure
Cataract progression
Visual Acuity
Total power delivered by each laser modality
Iridotomy patency and size
Pain rating during the procedure
Anterior segment inflammation
Endothelial cell count
Rate of complications

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paul Chew, FRCSEd,MMed, National University Hospital, Singapore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Primary Completion (Actual)

December 1, 2007

Study Completion (Actual)

December 1, 2007

Study Registration Dates

First Submitted

March 27, 2007

First Submitted That Met QC Criteria

March 27, 2007

First Posted (Estimate)

March 28, 2007

Study Record Updates

Last Update Posted (Estimate)

May 14, 2008

Last Update Submitted That Met QC Criteria

May 12, 2008

Last Verified

May 1, 2008

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Angle Closure Glaucoma

Clinical Trials on Q-switched fd Nd:yag in Laser Iridotomy

3
Subscribe